In this next episode of our 3-part series with exciting POC diagnostics start-up, ProtonDx.
Nathan sits down with the company's Chairman & President, Bob Enk, as well as Dr. Jesus Rodriguez Manzano, Chief Scientific Officer for an exclusive chat about the future of diagnostics with ProtonDx.
Dr. Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes single-molecule technologies, machine learning applied to healthcare, and clinical diagnostics, with a particular interest in low- and middle-income countries. He is the author of over 90 scientific publications and 14 international patent applications and helped co-found ProtonDx just over 3 years' ago.
Bob Enk is Chairman and President at ProtonDx. An experienced investing pioneer and CEO with an alternative mindset and demonstrated history of innovation and growth across financial services and healthcare. After joining the business nearly 2 years ago to take it to the next level in its stratospheric growth, he offers insight into his industry experience interacting with key players and clients, working with strategic partners and major investors, and loads more.
From the stimulus for this impressive brand to the reality of using point-of-care to tackle infectious disease in 2023 and beyond. Listen to learn more about new possibilities with lab-on-chip,
the vision for developing ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need, and the plan to commercialise this essential testing kit.
If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at firstname.lastname@example.org or let's connect on LinkedIn.
Want to collaborate with us? Charlton Morris is a Talent Solutions business who offer search, contract, volume and employer branding solutions to the life science markets.
Feature in articles, videos, podcasts and more.